AVADEL PHARMACEUTICALS PLC (AVDL) - Dilution Analysis

10-Q filing | 97.1M shares outstanding

10-Q filing | 96.7M shares outstanding

10-Q filing | 96.6M shares outstanding

8-K filing: Avadel Pharmaceuticals plc approved equity grants to its executives, including options to purchase ordinary shares and restricted share awards, with vesting conditions based on the company's share price performance.

10-K filing | 95.1M shares outstanding

10-Q filing | 96.3M shares outstanding

10-Q filing | 96.2M shares outstanding

8-K filing: Avadel Pharmaceuticals plc entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell Ordinary Shares up to $100,000,000 and terminated the previous ADS Sales Agreement upon the direct listing of Ordinary Shares on the Nasdaq Stock Market. ($13.5M proceeds)

10-Q filing | 91.7M shares outstanding

10-K filing | 90.6M shares outstanding

10-Q filing | 89.4M shares outstanding

10-Q filing | 89.4M shares outstanding

8-K filing: Avadel Finance exercised its option to exchange $106,268,000.00 aggregate principal amount of its 6.00% Exchangeable Senior Notes due 2027 for approximately 12.3 million American Depositary Shares and $1.47 million in cash, with the exchange scheduled to close on June 26, 2023.

10-Q filing | 76.8M shares outstanding

8-K filing: Avadel Pharmaceuticals plc closed a public offering of ordinary shares and Series B Non-Voting Convertible Preferred Shares, with gross proceeds of approximately $143.8 million. ($287.6M proceeds)

8-K filing: Avadel Pharmaceuticals plc entered into an underwriting agreement for a public offering of ordinary shares and Series B Non-Voting Convertible Preferred Shares, with expected net proceeds of approximately $117.0 million, potentially increasing to $134.6 million if the underwriters exercise their option in full. ($234.0M proceeds)

10-K filing | 60.1M shares outstanding

10-Q filing | 60.2M shares outstanding

S-3 filing: The filing is an S-3 shelf registration for the potential offering and sale of up to $500,000,000 in aggregate principal amount of ordinary shares, ordinary shares represented by American Depositary Shares, preferred shares, debt securities, warrants and/or units.

10-Q filing | 59.0M shares outstanding

10-Q filing | 58.8M shares outstanding

8-K filing: Avadel Finance Cayman Limited, a subsidiary of Avadel Pharmaceuticals plc, closed its exchange of approximately $117.4 million in Existing Notes and $5.6 million for approximately $117.4 million in New Notes due October 2, 2023, pursuant to Section 4(a)(2) of the Securities Act of 1933.

8-K filing: Avadel Pharmaceuticals plc, through its subsidiary Avadel Finance Cayman Limited, entered into exchange agreements to exchange approximately $117.4 million in aggregate principal amount of existing 4.50% Exchangeable Senior Notes due February 1, 2023 and approximately $5.6 million in cash for approximately $117.4 million in aggregate principal amount of new 4.50% Exchangeable Senior Notes due October 2, 2023.

10-K filing | 58.5M shares outstanding

10-Q filing | 58.6M shares outstanding

10-Q filing | 58.5M shares outstanding

10-Q filing | 58.4M shares outstanding

10-K filing | 54.9M shares outstanding

10-Q filing | 58.2M shares outstanding

10-Q filing | 37.3M shares outstanding

10-Q filing | 58.1M shares outstanding

S-3 filing: This is an S-3 filing for the resale of ordinary shares represented by American Depositary Shares by selling shareholders.

8-K filing: Avadel Pharmaceuticals plc entered into an underwriting agreement for a public offering of 11,630,000 American Depositary Shares at $10.75 per share, with expected net proceeds of approximately $117.1 million. ($117.1M proceeds)

10-K filing | 41.8M shares outstanding

8-K filing: Avadel Pharmaceuticals plc entered into a Securities Purchase Agreement to sell 8,680,225 ordinary shares and 487,614 Series A Non-Voting Convertible Preferred Shares at $7.09 per share, resulting in gross proceeds of approximately $65 million. ($65.0M proceeds)

S-3 filing: The filing is for a shelf offering of ordinary shares, ordinary shares represented by American Depositary Shares, preferred shares, debt securities, warrants and/or units up to an aggregate principal amount of $250,000,000.